Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | MPL | P40238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17988060 | 0.88 | LMNA (0.46) | LMNAELANEKDM4EPOLBLRRK2 | |
| SCHEMBL21130278 | 0.86 | LMNA (0.49) | LMNAELANEKDM4EPOLB | |
| SCHEMBL21130275 | 0.84 | LMNA (0.52) | LMNAELANEKDM4EPOLBPTPN2 | |
| SCHEMBL17087996 | 0.81 | LMNA (0.46) | LMNAELANEKDM4EPOLB | |
| SCHEMBL21130276 | 0.81 | LMNA (0.56) | LMNAELANEKDM4EPOLBPTPN2 | |
| SCHEMBL21130279 | 0.80 | LMNA (0.58) | LMNAELANEKDM4EPOLBCYP11B2 | |
| SCHEMBL2706715 | 0.80 | LMNA (0.56) | LMNAELANEKDM4EPOLB | |
| SCHEMBL19914259 | 0.79 | LRRK2 (0.44) | LMNAELANEKDM4EPOLBHSPD1 | |
| SCHEMBL21130359 | 0.78 | LMNA (0.41) | LMNAELANEKDM4EPOLBPDE2A | |
| SCHEMBL19749169 | 0.78 | LMNA (0.54) | LMNAELANEKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | LMNA 1548/4885ELANE 240/4885KDM4E 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.